Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
Francesco Panza, Davide Seripa, Vincenzo Solfrizzi, et al.
Expert Opinion on Emerging Drugs (2016) Vol. 21, Iss. 4, pp. 377-391
Closed Access | Times Cited: 55

Showing 26-50 of 55 citing articles:

Azeliragon ameliorates Alzheimer’s disease via the Janus tyrosine kinase and signal transducer and activator of transcription signaling pathway
Lijuan Yang, Yepei Liu, Yuanyuan Wang, et al.
Clinics (2021) Vol. 76, pp. e2348-e2348
Open Access | Times Cited: 23
Cognitive impairment in heart failure: clinical implications, tools of assessment, and therapeutic considerations
Sotiria Liori, Angelos Arfaras-Melainis, Vasiliki Bistola, et al.
Heart Failure Reviews (2021) Vol. 27, Iss. 4, pp. 993-999
Closed Access | Times Cited: 21
Rationale for the development of an Alzheimer’s disease vaccine
Ping Kwan, Haruki Konno, Ka‐Hou Chan, et al.
Human Vaccines & Immunotherapeutics (2019) Vol. 16, Iss. 3, pp. 645-653
Open Access | Times Cited: 25
Curcumin and Novel Synthetic Analogs in Cell-Based Studies of Alzheimer’s Disease
Stella Gagliardi, Valentina Franco, Stefano Sorrentino, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 21
The amyloid-inhibiting NCAM-PrP peptide targets Aβ peptide aggregation in membrane-mimetic environments
Sylwia Król, Nicklas Österlund, Faraz Vosough, et al.
iScience (2021) Vol. 24, Iss. 8, pp. 102852-102852
Open Access | Times Cited: 17
Danger-associated molecular pattern molecules and the receptor for advanced glycation end products enhance ANCA-induced responses
Theresa H. Page, Derick Chiappo, Francesca Brunini, et al.
Lara D. Veeken (2021) Vol. 61, Iss. 2, pp. 834-845
Open Access | Times Cited: 13
Maysin and Its Flavonoid Derivative from Centipedegrass Attenuates Amyloid Plaques by Inducting Humoral Immune Response with Th2 Skewed Cytokine Response in the Tg (APPswe, PS1dE9) Alzheimer’s Mouse Model
Yuno Song, Hong-Duck Kim, Min-Kwon Lee, et al.
PLoS ONE (2017) Vol. 12, Iss. 1, pp. e0169509-e0169509
Open Access | Times Cited: 16
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease
Miren Ettcheto, Oriol Busquets, Triana Espinosa-Jiménez, et al.
Current Pharmaceutical Design (2020) Vol. 26, Iss. 12, pp. 1286-1299
Closed Access | Times Cited: 13
Ethical and Social Implications of Using Predictive Modeling for Alzheimer’s Disease Prevention: A Systematic Literature Review
Zuzanna Angehrn, Jelena Sostar, Clémentine Nordon, et al.
Journal of Alzheimer s Disease (2020) Vol. 76, Iss. 3, pp. 923-940
Open Access | Times Cited: 12
Anti-tau vaccine in Alzheimer's disease: a tentative step
Francesco Panza, Giancarlo Logroscino
The Lancet Neurology (2016) Vol. 16, Iss. 2, pp. 99-100
Closed Access | Times Cited: 11
Causal Relationships Between Relative Intake from the Macronutrients and Alzheimer’s Disease: A Two-Sample Mendelian Randomization Study
Xiaoxin Wang, Hongru Sun, Sijia Pan, et al.
Journal of Alzheimer s Disease (2022) Vol. 87, Iss. 2, pp. 665-673
Closed Access | Times Cited: 7
Calprotectin influences the aggregation of metal-free and metal-bound amyloid-β by direct interaction
Hyuck Jin Lee, Masha G. Savelieff, Juhye Kang, et al.
Metallomics (2018) Vol. 10, Iss. 8, pp. 1116-1127
Open Access | Times Cited: 10
The Mode of Action of an Anti-Oligomeric Amyloid β-Protein Antibody Affects its Protective Efficacy
Yunlong Zhang, Yangyang Huai, Xiaoning Zhang, et al.
Neurotoxicity Research (2018) Vol. 35, Iss. 2, pp. 304-317
Closed Access | Times Cited: 8
Current Trends in the Development of Drugs for the Treatment of Alzheimer’s Disease and their Clinical Trials
С. О. Бачурин, Elena Bovina, A. A. Ustyugov
Biomedical Chemistry Research and Methods (2018) Vol. 1, Iss. 3, pp. e00015-e00015
Open Access | Times Cited: 8
Novel ketone body therapy for managing Alzheimer's disease
Michelle A. Puchowicz, Thomas N. Seyfried
Journal of Neurochemistry (2017) Vol. 141, Iss. 2, pp. 162-164
Open Access | Times Cited: 6
Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status
Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker
Therapeutic Innovation & Regulatory Science (2019), pp. 216847901987406-216847901987406
Closed Access | Times Cited: 6
Multi-Target-Directed Ligand Approach in Anti-Alzheimer’s Drug Discovery
Vaishali M. Patil, Neeraj Masand, Vertika Gautam, et al.
(2023), pp. 285-319
Closed Access | Times Cited: 2
Contribution of Mediterranean Diet in the Prevention of Alzheimer’s Disease
Francesco Panza, Madia Lozupone, Vincenzo Solfrizzi, et al.
Elsevier eBooks (2018), pp. 139-155
Closed Access | Times Cited: 5
New hope for Alzheimer’s dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis
Stephen M. Stahl
CNS Spectrums (2018) Vol. 23, Iss. 5, pp. 291-297
Open Access | Times Cited: 5
A simple method for modeling amyloid kinetics featuring position biased fiber breakage
Damien Hall
Biophysics and Physicobiology (2020) Vol. 17, pp. 30-35
Open Access | Times Cited: 5
Translation of imaging biomarkers from clinical research to healthcare
Ingo Kilimann, Jochen René Thyrian, Wolfgang Hoffmann, et al.
Zeitschrift für Gerontologie und Geriatrie (2017) Vol. 50, Iss. S2, pp. 84-88
Closed Access | Times Cited: 3
Alzheimer’s Disease: Cellular and Pharmacological Aspects
Gonzálo Emiliano Aranda-Abreu, Fausto Rojas-Durán, Marı́a Elena Hernández, et al.
Geriatrics (2024) Vol. 9, Iss. 4, pp. 86-86
Open Access
The use of plasma exchange with albumin replacement in the management of Alzheimer’s disease: a scoping review
Yahveth Cantero‐Fortiz, Merçé Boada
Frontiers in Neurology (2024) Vol. 15
Open Access
New drugs for Alzheimer’s disease: Aducanumab or Donanemab?
Mehran Joodaki, Mona Merati Shirazi, Nasrin Hosseini
Deleted Journal (2024) Vol. 28, Iss. 3, pp. 219-236
Open Access
Ethical and social implications of using predictive modeling for Alzheimer’s disease prevention: a systematic literature review protocol
Zuzanna Angehrn, Clémentine Nordon, Andrew Turner, et al.
BMJ Open (2019) Vol. 9, Iss. 3, pp. e026468-e026468
Open Access | Times Cited: 3

Scroll to top